[Epithelioid angiomyolipoma of the kidney after successfully treated malignant melanoma].

Urologe A

Carl-Thiem-Klinikum Cottbus, Thiemstraße 111, 03048, Cottbus, Deutschland.

Published: February 2022

AI Article Synopsis

Article Abstract

Background: Therapy of epitheloid angiomyolipomas (eAML) may be challenging, since unlike classical angiomyolipomas this rare subclass of benign mesenchymal angiomyolipomas may present with lymph node metastases, local recurrent disease, and/or systemic metastatic disease in up to 30% of cases.

Objectives: We report here for the first time in Germany a case of eAML after successful treatment of malignant melanoma.

Materials And Methods: Clinical and histological findings as well as results of the genetic analysis of the angiomyolipoma are presented.

Results: A somatic, truncating mutation of the TSC2 gene was found in the angiomyolipoma.

Conclusion: The relationship to histologically similar tumor entities are presented and therapeutic options based on the genetic classification are discussed.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8831349PMC
http://dx.doi.org/10.1007/s00120-021-01662-xDOI Listing

Publication Analysis

Top Keywords

[epithelioid angiomyolipoma
4
angiomyolipoma kidney
4
kidney treated
4
treated malignant
4
malignant melanoma]
4
melanoma] background
4
background therapy
4
therapy epitheloid
4
epitheloid angiomyolipomas
4
angiomyolipomas eaml
4

Similar Publications

A 55-year-old man with tuberous sclerosis complex (TSC) was diagnosed with left renal angiomyolipoma (AML), a group of perivascular epithelioid cell tumors called PEComas. He had received the mTOR inhibitor everolimus, which resulted in a complete response. However, a left renal mass relapsed in two years, followed by the occurrence of a hepatic mass five months later.

View Article and Find Full Text PDF

Aims: The hepatic perivascular epithelioid cell tumour (PEComa), including angiomyolipoma, exhibits diverse morphology and clinical behaviour; however, its prognostic features remain undefined. This study aimed to investigate its histological features and prognostic factors.

Methods And Results: In total, 132 patients were included.

View Article and Find Full Text PDF

Perivascular epithelioid cell tumors (PEComas) are rare mesenchymal neoplasms, commonly found in the uterus and retroperitoneum. Renal PEComas are exceedingly rare, often posing diagnostic challenges due to their resemblance to renal cell carcinoma (RCC) on imaging. We present the case of an 18-year-old male who presented with non-specific symptoms of fever, chills, and shivering.

View Article and Find Full Text PDF

BACKGROUND Perivascular epitheloid cell neoplasm (PEComa) is a rare mesenchymal tumor that is evaluated in the same tumor family as angiomyolipoma, sugar cell tumor of the lung, and lymphangioleiomyomatosis. Immunohistochemically, the disease can express melanocytic and myogenic markers, such as HMB45, HMSA1, MelanA/Mart1, and actin. The disease can be seen in almost every organ, especially the uterus and retroperitoneum.

View Article and Find Full Text PDF

Ceus features of liver pecoma: a case report and literature review.

J Ultrasound

November 2024

Diagnostic and Therapeutic Interventional Ultrasound Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico Sant'Orsola-Malpighi, via Massarenti n 9, 40138, Bologna, Italy.

Perivascular epithelioid cell neoplasms (PEComas) and epithelioid angiomyolipomas (EAMLs) are two different denominations for the same "mesenchymal tumor composed of histologically and immunohistochemically distinctive perivascular epithelioid cells". Hepatic PEComa/EAML is a very rare neoplasm, and only 29 case reports of hepatic PEComa and 25 of hepatic EAML have been reported in the current literature. A clear female predominance with a mean age at diagnosis of 42.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!